Literature DB >> 18622676

Pharmacokinetic-pharmacodynamic target attainment analysis of cefozopran in Japanese adult patients.

Kazuro Ikawa1, Kenichi Nomura, Norifumi Morikawa, Kayo Ikeda, Hiroki Ohge, Taijiro Sueda, Masafumi Taniwaki.   

Abstract

This study aimed to perform a pharmacokinetic-pharmacodynamic (PK-PD) target attainment analysis to create a dosing strategy for cefozopran in Japanese adult patients. A total of 145 plasma concentration samples from 32 adult patients were used for a population pharmacokinetic modeling and Monte Carlo simulation to assess the probability of attaining the PK-PD target (70% of the time above the minimum inhibitory concentration for the bacterium). The final population pharmacokinetic model was based on a two-compartment model, and creatinine clearance (Cl(cr)) and body weight (BW) were the most significant covariates: Cl(l/h) = 0.0263 x Cl(cr) + 1.49, V (c)(l) = 0.185 x BW(0.931), Q(l/h) = 4.55, V (p)(l) = 5.86, where Cl is the clearance, V (c) is the volume of distribution of the central compartment, Q is the intercompartmental clearance, and V (p) is the volume of distribution of the peripheral compartment. The Monte Carlo simulation demonstrated that 1 g q 12 h achieved a PK-PD target attainment probability of > or =85% against Escherichia coli, Klebsiella pneumoniae, and Streptococcus pneumoniae isolates. However, against Haemophilus influenzae and Pseudomonas aeruginosa isolates, 1 g q 8 h and (2 g, 1 g, 1 g) q 8 h were required to achieve a high probability, which value varied with the Cl(cr) and BW of the patient. These results provide a PK-PD-based strategy for tailoring cefozopran regimens in Japanese adult patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18622676     DOI: 10.1007/s10156-008-0589-0

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  1 in total

1.  Pharmacokinetics of cefozopran by single and multiple intravenous infusions in healthy Chinese volunteers.

Authors:  G L Wu; J Z Shentu; H L Zhou; M X Zhu; X J Hu; J Liu; L H Wu
Journal:  Drugs R D       Date:  2015-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.